Mefena

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mefena

This section provides a factual definition of Mefena based on its composition, classification, and general function, adhering strictly to non-commercial data.


Property Description
Active ingredient Mefenamic Acid (INN)
Form Oral Capsule
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common purpose Relief of mild-to-moderate pain, inflammation, and fever
Origin Synthetic organic compound

What Type of Medicine is Mefena? (Identity and Classification)

Mefena is a prescription pharmaceutical product whose pharmacological identity is defined by its sole active component, the internationally nonproprietary name (INN) Mefenamic Acid. It is officially classified as an Nonsteroidal Anti-inflammatory Drug (NSAID), a group of agents recognized for their ability to modify pain and inflammation pathways. Mefenamic Acid belongs to the specialized fenamate subclass, which is characterized chemically as an anthranilic acid derivative. This classification distinguishes its structure from other major NSAID groups, positioning it as a distinct, yet established, therapeutic option. The compound is a synthetic organic molecule and is typically formulated as a monotherapy, containing no other active ingredients, delivered as an oral capsule.

General Purpose and Physiological Effect (High-Level Action)

The primary purpose of Mefena is to provide relief from mild to moderate pain and to decrease associated symptoms of inflammation and fever. Mefenamic Acid achieves this effect by acting as a cyclooxygenase (COX) inhibitor, a mechanism that blocks the body's synthesis of prostaglandins. Prostaglandins are key cellular signaling molecules that drive inflammatory responses and pain sensation. By interrupting this pathway, Mefena addresses the source of discomfort. This dual action makes the medicine suitable for managing self-limiting pain conditions. Mefena helps ease general discomfort by targeting the body's pain and inflammatory pathways.

Regulatory References

  1. Nonsteroidal Anti-inflammatory Drug (NSAID)
  2. Mefenamic Acid

What side effects are possible with Mefena?

Mefena: Possible Side Effects and Safety Information

Serious Adverse Reactions and Regulatory Warnings

Mefena, a nonsteroidal anti-inflammatory drug (NSAID), is associated with an increased risk of serious, potentially fatal cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke. This risk may increase with higher doses and longer duration of use, particularly in patients with pre-existing CV disease or risk factors. It is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.

Additionally, NSAIDs increase the risk of serious gastrointestinal (GI) adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines, which can occur without warning and may be fatal. These risks are higher in the elderly.

Common Adverse Reactions

Adverse reactions most frequently affect the gastrointestinal system. Common reactions include diarrhea, abdominal pain, nausea, vomiting, dyspepsia (indigestion), flatulence, constipation, and heartburn. Headache, dizziness, and tinnitus (ringing in the ears) are also commonly reported.

Other Clinically Significant Safety Information

  • Serious Skin Reactions: Rare but serious skin reactions have been reported, including exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Treatment should be discontinued immediately at the first sign of a rash or hypersensitivity reaction.
  • Renal and Hepatic Effects: The drug can cause renal toxicity, including acute renal failure, and should not be used in patients with pre-existing renal disease or significantly impaired renal function. Liver function elevations and rare cases of clinically apparent liver injury have been reported.
  • Population-Specific Restrictions: Mefena is contraindicated in patients with active GI ulceration, a history of asthma or allergic-type reactions to aspirin or other NSAIDs, or severe heart failure. Use during the third trimester of pregnancy is restricted due to the risk of fetal harm and potential complications with delivery.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Mefena (Mefenamic Acid) overdose describes acute presentations primarily involving the gastrointestinal (GI) and Central Nervous System (CNS). Documented manifestations include nausea, vomiting, epigastric pain, lethargy, and drowsiness. Severe outcomes can involve gastrointestinal bleeding, acute renal failure, respiratory depression, and hypertension.

A particular concern noted in official labeling is the elevated risk of CNS toxicity, including convulsions (seizures) and coma, which is significantly higher for Mefena compared to other nonsteroidal anti-inflammatory drugs (NSAIDs). Metabolites of the drug may accumulate in patients with pre-existing renal or hepatic failure.

Immediate Emergency Action

In the event of suspected overdose, regulators mandate that individuals seek immediate medical attention. Emergency services must be contacted instantly if the affected person has collapsed, had a seizure, is experiencing trouble breathing, or cannot be awakened.

Management of overdose is exclusively by symptomatic and supportive care, as no specific antidotes are known. Official procedures include the use of activated charcoal and gastric lavage for decontamination. Due to the high protein binding, advanced removal techniques like forced diuresis or hemodialysis are not typically useful.

Therapeutic Uses of Mefena

What Mefena Treats: Main Uses and Benefits

Mefena (Mefenamic Acid) is commonly used to address symptoms related to physical discomfort and inflammatory or irritative states. Its uses are applied across domains involving pain, inflammation, and specific gynecological symptoms.

Supportive Symptom Management

The medication is frequently applied in conditions characterized by specific episodic symptom patterns, including providing targeted assistance for the painful abdominal cramping of primary dysmenorrhea and offering therapeutic support by reducing excessive blood loss in cases of menorrhagia. This symptomatic relief may help patients cope more steadily with difficult monthly episodes.

It is also relevant in contexts marked by increased discomfort or tension, such as headaches, muscular aches, and dental pain. Applied in clinical settings that involve acute or unstable symptom patterns, the medication is often used during phases when symptoms become more noticeable, helping to ease the overall symptom burden of fever and localized swelling.


Quick Fact: Support for Episodic Manifestations

Mefena is commonly used across conditions presenting with acute episodes, providing targeted relief for the intense, cyclical abdominal cramping associated with menstruation.

Regulatory References

  1. authoritative drug product information

Eligibility and Restrictions for Use

Eligibility and Contraindications for Mefena (Mefenamic Acid)

Official regulatory documents strictly define the patient populations eligible for Mefena and those for whom use is prohibited. The medicine is primarily intended for adults and adolescents ge 14 years of age. Use is generally not recommended for the capsule/tablet formulation in children under 14, as safety and efficacy are not established for this group.

Use is absolutely contraindicated in patients with a known hypersensitivity to mefenamic acid or any NSAID, including aspirin-precipitated asthma, and in those with active gastrointestinal ulceration, Inflammatory Bowel Disease, or a history of GI bleeding. It is also prohibited for patients with severe hepatic, renal, or heart failure, and for pain management following Coronary Artery Bypass Graft (CABG) surgery.

Specific restrictions apply to reproductive status and the elderly. Mefena is contraindicated in the third trimester of pregnancy and is not recommended for women who are breastfeeding or actively attempting to conceive. Geriatric patients face an increased risk of adverse reactions and should only use the medicine under restricted conditions.

What should I know about interactions with other medicines?

Officially Documented Drug-Drug Interactions

Mefena (Mefenamic Acid) interacts through documented patterns primarily focused on pharmacodynamic risk reinforcement and alterations in systemic exposure. The medicine is contraindicated for pain management in the peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery. Concurrent use with other systemic non-aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is advised against due to the high risk of serious gastrointestinal events.

Pharmacodynamic interactions involve substances that increase a specific clinical risk. Co-administration with oral anticoagulants (e.g., Warfarin), SSRIs, or Corticosteroids heightens the risk of bleeding and hemorrhage. Mefena officially interferes with the anti-platelet effect of low-dose Aspirin.

Furthermore, the efficacy of anti-hypertensives, including ACE Inhibitors, Angiotensin II Antagonists, and Diuretics, may be reduced. This combination also carries a documented risk of deteriorating renal function, particularly in elderly patients or those with existing impairment.

Substances that alter systemic exposure include Lithium and Methotrexate, whose plasma concentrations may be increased due to reduced clearance. Additionally, co-ingestion with antacids containing magnesium hydroxide has been shown to significantly increase Mefena's absorption rate. Consumption of Alcohol (Ethanol) is associated with an increased risk of stomach bleeding.

Mechanism of Action

How Mefena Works

Mefena's mechanism focuses on chemically intervening in specific biological pathways to alter signaling dynamics. Its effect profile is achieved through a multi-domain action that is both peripheral and specialized to its subclass.


⌨️ Interruption of Eicosanoid Synthesis via COX Enzymes

Mefena operates as a non-selective inhibitor of the Cyclooxygenase ( COX-1 and COX-2) enzymes, which are necessary for converting arachidonic acid into Prostaglandins, which are key cellular signaling mediators. By blocking these molecular steps, the drug modifies early pathway activity, resulting in a reduction of inflammatory mediators and the modulation of the hypothalamic thermal set-point.


Specialized Modulation of Signaling Pathways

Beyond enzyme inhibition, Mefenamic Acid engages mechanisms that regulate other dysregulated processes. It acts as a direct antagonist on specific Prostaglandin receptors, which functions to constrain the effects of high mediator concentration, particularly in smooth muscle tissues. This specialized interaction leads to predictable physiological adjustments, such as the reduction of smooth muscle contraction activity and decreased local afferent nerve fiber sensitization.


Non-Selective Mechanistic Constraint

The drug's non-selective inhibition pattern means it modifies cascades associated with both pathophysiological ( COX-2) and normal COX-1 functions. This mechanism acts by suppressing the output of heightened inflammatory pathways, and simultaneously engages systems involved in regulatory feedback within pathways, which is a characteristic constraint of non-selective NSAID mechanisms. The result is a broad suppression of PGE2-driven signaling across multiple systems.

Dosage and Administration Information

How to Use Mefena (Administration Guidelines)

Administration of Mefena, which contains the active ingredient Mefenamic Acid, follows structured protocols focusing strictly on the dosage, frequency, route, and duration of use. The medication is intended for oral administration as capsules.

Standard Use and Dosing Regimens

The established regimen for acute pain and primary dysmenorrhea in adults (14 years of age and older) is initiated with a specific starting dose, followed by a fixed maintenance schedule.

Administration Scope Protocol Detail
Route of Administration Oral only, typically as a 250 mg capsule.
Starting Dose 500 mg taken orally once for initiation of therapy.
Maintenance Dose 250 mg taken orally, with a frequency of every 6 hours as needed (q6hr).

Labeled Conditions and Duration Principles

Guidelines involve adherence to specific intake conditions and the strict limitation of treatment duration.

Contextual Intake: Each dose is typically taken with food or milk (or a full glass of water) to minimize potential gastrointestinal effects.

Duration Constraint: Mefena is restricted to short-term use. For acute pain, treatment should not exceed seven days. For primary dysmenorrhea, use is typically limited to the duration of symptoms, often two to three days per cycle. The overarching principle requires using the lowest effective dose for the shortest duration possible.

Missed Dose Rule: If a dose is missed, the protocol is to skip the missed dose if it is almost time for the next scheduled dose; doses are not to be doubled to make up for a missed one.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Mefena

This section summarizes the types of official research available for Mefena (Mefenamic Acid), describing the study contexts and what has been measured, without providing medical advice or guidance on how the medicine should be used.


Evidence for Use in Primary Dysmenorrhea (Menstrual Pain)

Research exploring how symptoms change over time in primary dysmenorrhea has primarily utilized Randomized Controlled Trials (RCTs). These studies were designed to assess short-term, episodic symptom patterns in adult women and adolescents. In these settings, researchers monitored outcomes related to physical discomfort and tracked whether participants requested additional study medication.

The findings from these trials have described measurements of reported pain levels that were documented during the study period. This evidence contributes to understanding symptom patterns associated with menstrual cramping, an acute condition characterized by episodic manifestations. However, the existing evidence focuses almost exclusively on short-term relief during a few cycles, and follow-up durations were limited.


Evidence for Use in Mild-to-Moderate Acute Pain

Mefena was evaluated in research contexts involving fluctuating or unstable symptoms typical of acute pain, such as pain following minor surgery. Studies commonly used single-dose Randomized Controlled Trials. Outcomes included measuring pain intensity over a defined, short time interval and monitoring the duration before participants requested further pain relief. Research provides insight into the short-term measurements of pain intensity that were collected.

Despite the available evidence, data for general, non-specific acute pain is sometimes limited compared to other analgesic agents. The existing research is restricted to short-term use, consistent with regulatory clearances for acute symptoms. Long-term effects are not fully established because trials were not designed for chronic or persistent pain.


What is Still Uncertain About Mefena Research

Research evidence describes data collected for Mefena; results apply only to the specific conditions and populations studied. One key limitation is that comparative evidence is lacking for many head-to-head trials against the most current treatments available for pain and menorrhagia. Data for certain special populations, such as older adults with comorbidities, remain insufficient. Further investigation is needed to fully establish the long-term effects and safety monitoring for repeated, episodic use across the lifespan.

Key Studies & References

  1. Clinical Guidance for Primary Dysmenorrhea Management (ACOG/NICE equivalent supporting evidence base)

Frequently Asked Questions (FAQ)

Common questions about Mefena (FAQ)


Q: What are the most important medications to avoid while using Mefena?

Regulatory documents advise against taking Mefena with other non-aspirin NSAIDs due to a heightened risk of serious stomach and intestinal problems. Official product information also notes that co-administration with blood thinners (like warfarin) or certain antidepressants (SSRIs) is associated with an increased risk of bleeding. Additionally, Mefena may reduce the effectiveness of blood pressure medications, such as ACE inhibitors and diuretics.


Q: Is it true that Mefena is often used for menstrual pain?

Yes, Mefena is officially indicated for the relief of mild-to-moderate pain, which specifically includes the treatment of primary dysmenorrhea. This is the medical term for painful menstrual cramps. Studies summarized in regulatory documents support its use for short-term observed changes in symptom measures during these episodes.


Q: Can taking Mefena affect my blood pressure readings?

Official warnings note that Mefena can potentially lead to the onset of new high blood pressure or worsen high blood pressure that a person already has. Official guidance notes that Mefena should be used with caution in individuals with pre-existing blood pressure concerns. The medication may also interfere with the effectiveness of prescribed anti-hypertensive drugs.


Q: Can Mefena cause fluid retention or swelling?

Regulatory documents indicate that Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like Mefena may be associated with edema, which is swelling caused by fluid retention. Regulatory documents note that caution is required when prescribing the medicine to patients with conditions like heart failure, who may be sensitive to this effect.


Q: Can Mefena be used if someone has asthma?

Mefena is strictly contraindicated (prohibited) for use in patients who have a history of asthma, hives, or other serious allergic reactions that were triggered by aspirin or any other NSAID. The restriction is in place due to the documented risk of serious allergic-type reactions in this population.


Q: Is Mefena the same as or very similar to over-the-counter pain relievers?

Mefena belongs to the same general pharmacological class—Nonsteroidal Anti-inflammatory Drugs (NSAIDs)—as some over-the-counter pain relievers. However, Mefena is chemically classified in the fenamate subclass and, in the United States and many other regions, it is available only as a prescription-only medicine (Rx-only).


Q: Does Mefena have a common side effect of making you feel sleepy?

Yes, regulatory documents list drowsiness (somnolence) as a known adverse reaction to Mefena. This is categorized as a central nervous system effect.


Q: Are stomach problems a frequent concern when taking Mefena?

Official warnings state that adverse reactions most frequently affect the gastrointestinal system. Common adverse reactions include diarrhea, abdominal pain, nausea, and vomiting. Official guidance specifies that each dose should be taken with food or milk.


Q: How quickly should I expect Mefena to start working after taking it?

Pharmacokinetic studies show that Mefena is rapidly absorbed after being taken orally. Mean peak plasma levels, which indicate when the drug is most concentrated in the bloodstream, are typically measured within two to four hours after a single dose.


Q: How long does the effect of one dose of Mefena usually last?

Pharmacokinetic data indicates that Mefena has an elimination half-life of approximately two hours.


Q: Is Mefena something I can take only when needed, or does it require regular use?

Mefena is intended for short-term use to manage acute symptoms of pain or menstrual cramps, and it is typically taken on an 'as needed' basis (p.r.n.) on a fixed schedule. Mefena is not intended for continuous long-term use.


Q: Are there different strengths or formulations of Mefena available?

Yes, official regulatory labeling lists the primary form as a 250 mg oral capsule. Depending on the region and the specific manufacturer, Mefenamic Acid is also noted to be available in other strengths, such as a 500 mg capsule or tablet.


Q: Is it normal to feel a bit lightheaded the first time I take Mefena?

Official regulatory documents list both dizziness and lightheadedness as known side effects that can occur while taking Mefena. However, official product labeling does not specifically detail whether these symptoms are more common or intense upon the very first use.


Q: Does Mefena interact with common supplements like vitamin D or magnesium?

Official drug interaction documents specifically note that antacids containing magnesium hydroxide significantly increase the rate at which Mefena is absorbed by the body. Interactions with other general supplements, such as Vitamin D, are not detailed in the core product labeling.


Q: Is there a maximum number of days or weeks Mefena can be used continuously?

Yes, Mefena is strictly restricted to short-term use. For acute pain, treatment is advised not to exceed seven days (one week). For menstrual pain, use is typically limited to the duration of symptoms, often two to three days.


Q: Do you need a prescription for Mefena in most places?

Yes, Mefena (Mefenamic Acid) is categorized as a prescription-only medicine in the United States and many other regulatory regions, including the UK and Canada.


Q: Can Mefena interfere with birth control pills?

Official product labeling does not provide specific data on all oral contraceptives. However, drug interaction warnings indicate that NSAIDs like Mefena may potentially interact with certain hormonal components of some birth control medications, which is associated with an increased risk of potassium levels.


Q: Does Mefena change how other pain medications work?

Mefena is known to interact with other pain medications. Regulatory warnings advise against using it concurrently with other non-aspirin NSAIDs. Furthermore, the drug is documented to interfere with and reduce the anti-platelet effect that low-dose aspirin has.


Q: Is Mefena recommended for pain from dental work?

Mefena is officially indicated for the relief of mild to moderate acute pain. While the labeling does not single out dental work, the general indication for acute pain can cover short-term painful conditions like post-dental procedures.


Q: What research exists about Mefena's long-term safety?

Regulatory documents explicitly state that Mefena is restricted to short-term use. Long-term effects and safety monitoring for repeated, episodic use across the lifespan are not fully established because clinical trials were not designed to study chronic or persistent pain conditions.


Q: Does Mefena have a risk of dependency or addiction?

The classification of Mefena as an NSAID means it is not associated with the risk of dependency or addiction seen with certain other classes of pain medication.


Q: If Mefena makes me feel nauseous, is that something that goes away?

Nausea is listed as one of the common adverse reactions to Mefena, which most frequently affect the digestive system. However, regulatory documentation does not specifically detail the typical duration or persistence of this common side effect.


Q: Can Mefena be taken by people who are vegetarian or vegan?

Official inactive ingredient lists show that Mefena capsules contain gelatin in the shell. The capsule formulation also includes lactose monohydrate.


Q: Are there any specific patient groups Mefena is studied for more than others?

Yes, summaries of official research indicate that Mefena was most extensively evaluated in studies for the management of primary dysmenorrhea (menstrual pain) and for general mild-to-moderate acute pain conditions.


Q: Can Mefena cause changes in mood or anxiety?

Official adverse reaction reports include nervousness as a known, though less common, central nervous system side effect. While mood changes are not commonly listed, general psychiatric and nervous system effects are documented in official product information.

How should Mefena be stored and disposed of?

Storage and Disposal of Mefena (Mefenamic Acid)

Required Storage Conditions

Mefena capsules must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from light and stored in a dry place. It is required to keep Mefena in the original container, ensure the container is tightly closed, and store it out of the sight and reach of children.

Official Disposal Pathway

Discarding unused or expired Mefena should be done via a drug take-back program as the primary method. If a take-back program is not available, the medicine can be disposed of in household trash by mixing it with an undesirable substance in a sealed container. Disposal must always comply with local, federal, and state regulations, and the product should not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mefena found in:

A-Z Index: